Emerging thrombotic effects of drug eluting stents.
Lang
Ninian N
NN
Newby
David E
DE
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D023903:Coronary Restenosis / Q000517:prevention & control; D023921:Coronary Stenosis / Q000628:therapy; D003328:Coronary Thrombosis / Q000209:etiology* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D016503:Drug Delivery Systems; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000494:pharmacology; D015607:Stents / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000235:genetics / Q000378:metabolism; D015854:Up-Regulation / Q000235:genetics
D000970:Antineoplastic Agents; D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger; D010959:Tissue Plasminogen Activator; D017239:Paclitaxel; D020123:Sirolimus